Owkin Pricing & Plans 2026

Name: Owkin
Brand: Owkin
Availability: InStock

Complete pricing guide for Owkin. Compare all plans, analyze costs, and find the perfect tier for your needs.

Not sure if free is enough? See our Free vs Paid comparison →
Still deciding? Read our full verdict on whether Owkin is worth it →

🆓Free Tier Available

💎3 Paid Plans

⚡No Setup Fees

Choose Your Plan

Self-service access

$0 available self-service plan; no free trial, online checkout, or public paid seat price is offered

Start Free →

Enterprise partnership

Direct quote required; public list price is not published for enterprise contracts

Contact Sales →

Biopharma and research collaboration

Direct quote required; no public starting price or package price is listed

Start Free Trial →

Diagnostics and digital pathology programs

Direct quote required; diagnostic deployment pricing is not publicly listed

Start Free Trial →

Pricing sourced from Owkin · Last verified March 2026

Feature Comparison

Detailed feature comparison coming soon. Visit Owkin's website for complete plan details.

View Full Features →

Is Owkin Worth It?

✅ Why Choose Owkin

• Federated learning architecture via MOSAIC is designed to support training on real-world hospital data without centralizing patient records, potentially enabling access to diverse clinical datasets when appropriate agreements are in place
• FDA 510(k)-cleared MSIntuit CRC diagnostic provides regulatory evidence for a specific colorectal cancer MSI screening use case, with performance and workflow claims requiring review of FDA materials and validation data
• Strategic Sanofi partnership valued at over $180M (announced 2021) and Bristol Myers Squibb collaboration provide public partnership signals for pharmaceutical use cases
• Peer-reviewed publications in journals such as Nature Medicine and The Lancet Digital Health provide scientific credibility relative to less-published AI biotech peers
• Founded in 2016 with substantial reported funding and a global office presence, which may give institutional clients additional confidence in long-term vendor viability
• Multimodal approach combining pathology, genomics, spatial-omics and clinical data is intended to capture biological complexity beyond single-modality platforms

⚠️ Consider This

• Exclusively enterprise-focused with no self-service tier, making it inaccessible to individual researchers, small biotech startups, or academic labs without partnership agreements
• Heavy dependency on hospital data partnerships means geographic coverage and data diversity are limited by the willingness and ability of institutions to participate in federated networks
• Drug discovery timelines remain 3-5+ years from target identification to clinical proof-of-concept despite AI acceleration, and no Owkin-originated drug has yet reached late-stage clinical trials
• No publicly available pricing or standard contract terms, making cost comparison with alternatives like Recursion or Insilico Medicine difficult for prospective clients
• Limited public disclosure of model performance metrics and validation data outside of published research papers, making independent assessment of platform accuracy challenging

What Users Say About Owkin

👍 What Users Love

✓Federated learning architecture via MOSAIC is designed to support training on real-world hospital data without centralizing patient records, potentially enabling access to diverse clinical datasets when appropriate agreements are in place
✓FDA 510(k)-cleared MSIntuit CRC diagnostic provides regulatory evidence for a specific colorectal cancer MSI screening use case, with performance and workflow claims requiring review of FDA materials and validation data
✓Strategic Sanofi partnership valued at over $180M (announced 2021) and Bristol Myers Squibb collaboration provide public partnership signals for pharmaceutical use cases
✓Peer-reviewed publications in journals such as Nature Medicine and The Lancet Digital Health provide scientific credibility relative to less-published AI biotech peers
✓Founded in 2016 with substantial reported funding and a global office presence, which may give institutional clients additional confidence in long-term vendor viability
✓Multimodal approach combining pathology, genomics, spatial-omics and clinical data is intended to capture biological complexity beyond single-modality platforms

👎 Common Concerns

⚠Exclusively enterprise-focused with no self-service tier, making it inaccessible to individual researchers, small biotech startups, or academic labs without partnership agreements
⚠Heavy dependency on hospital data partnerships means geographic coverage and data diversity are limited by the willingness and ability of institutions to participate in federated networks
⚠Drug discovery timelines remain 3-5+ years from target identification to clinical proof-of-concept despite AI acceleration, and no Owkin-originated drug has yet reached late-stage clinical trials
⚠No publicly available pricing or standard contract terms, making cost comparison with alternatives like Recursion or Insilico Medicine difficult for prospective clients
⚠Limited public disclosure of model performance metrics and validation data outside of published research papers, making independent assessment of platform accuracy challenging
⚠Regulatory approval for AI diagnostics varies by jurisdiction, and expanding beyond FDA-cleared products to additional cancer types and international markets involves lengthy timelines

Pricing FAQ

What is federated learning and how does Owkin use it?

Federated learning is a machine learning approach where algorithms are sent to data sources, such as hospitals, rather than centralizing data in one location. Owkin describes MOSAIC as a platform that can train models across participating medical centers while keeping raw patient data within institutional environments and aggregating model learnings instead.

What is MSIntuit CRC and how does it work?

MSIntuit CRC is Owkin's FDA 510(k)-cleared AI diagnostic tool for detecting microsatellite instability in colorectal cancer from standard H&E-stained pathology slides. MSI status can affect treatment decisions, including immunotherapy eligibility. Procurement teams should review FDA clearance documentation and Owkin validation materials for exact intended use, performance, and workflow details.

How does Owkin compare to Recursion Pharmaceuticals and Insilico Medicine?

Owkin differentiates through its federated learning approach, which is designed to support access to real-world hospital data without centralization. Recursion Pharmaceuticals focuses on high-throughput biological experimentation and proprietary cellular imaging datasets. Insilico Medicine emphasizes generative AI for de novo molecule design and has its own clinical-stage drug candidates. Owkin's relative strength is hospital-connected biomedical AI, digital pathology, and oncology-focused clinical data collaboration.

What types of organizations can work with Owkin?

Owkin primarily partners with large pharmaceutical companies, academic medical centers, and hospital networks. The platform is not presented as a self-service product for individual researchers or clinical practitioners. Engagements appear to require negotiated enterprise or research collaboration agreements, with commercial terms varying by scope.

What cancer types does Owkin's platform cover?

Owkin's AI research and diagnostic pipeline spans multiple oncology indications including colorectal cancer, non-small cell lung cancer, breast cancer, mesothelioma, and hepatocellular carcinoma. Its computational pathology and biomarker discovery capabilities are positioned for solid tumor settings where digitized pathology slides and clinical outcome data are available through appropriate partnerships.

Ready to Get Started?

AI builders and operators use Owkin to streamline their workflow.

Try Owkin Now →

More about Owkin

Review Alternatives Free vs Paid Pros & Cons Worth It?Tutorial

Owkin Pricing & Plans 2026

Complete pricing guide for Owkin. Compare all plans, analyze costs, and find the perfect tier for your needs.

🆓Free Tier Available

💎3 Paid Plans

⚡No Setup Fees

Choose Your Plan

Self-service access

$0 available self-service plan; no free trial, online checkout, or public paid seat price is offered

Start Free →

Enterprise partnership

Direct quote required; public list price is not published for enterprise contracts

Contact Sales →

Biopharma and research collaboration

Direct quote required; no public starting price or package price is listed

Start Free Trial →

Diagnostics and digital pathology programs

Direct quote required; diagnostic deployment pricing is not publicly listed

Start Free Trial →

Pricing sourced from Owkin · Last verified March 2026

Is Owkin Worth It?

✅ Why Choose Owkin

• Federated learning architecture via MOSAIC is designed to support training on real-world hospital data without centralizing patient records, potentially enabling access to diverse clinical datasets when appropriate agreements are in place
• FDA 510(k)-cleared MSIntuit CRC diagnostic provides regulatory evidence for a specific colorectal cancer MSI screening use case, with performance and workflow claims requiring review of FDA materials and validation data
• Strategic Sanofi partnership valued at over $180M (announced 2021) and Bristol Myers Squibb collaboration provide public partnership signals for pharmaceutical use cases
• Peer-reviewed publications in journals such as Nature Medicine and The Lancet Digital Health provide scientific credibility relative to less-published AI biotech peers
• Founded in 2016 with substantial reported funding and a global office presence, which may give institutional clients additional confidence in long-term vendor viability
• Multimodal approach combining pathology, genomics, spatial-omics and clinical data is intended to capture biological complexity beyond single-modality platforms

⚠️ Consider This

• Exclusively enterprise-focused with no self-service tier, making it inaccessible to individual researchers, small biotech startups, or academic labs without partnership agreements
• Heavy dependency on hospital data partnerships means geographic coverage and data diversity are limited by the willingness and ability of institutions to participate in federated networks
• Drug discovery timelines remain 3-5+ years from target identification to clinical proof-of-concept despite AI acceleration, and no Owkin-originated drug has yet reached late-stage clinical trials
• No publicly available pricing or standard contract terms, making cost comparison with alternatives like Recursion or Insilico Medicine difficult for prospective clients
• Limited public disclosure of model performance metrics and validation data outside of published research papers, making independent assessment of platform accuracy challenging

What Users Say About Owkin

👍 What Users Love

✓Federated learning architecture via MOSAIC is designed to support training on real-world hospital data without centralizing patient records, potentially enabling access to diverse clinical datasets when appropriate agreements are in place
✓FDA 510(k)-cleared MSIntuit CRC diagnostic provides regulatory evidence for a specific colorectal cancer MSI screening use case, with performance and workflow claims requiring review of FDA materials and validation data
✓Strategic Sanofi partnership valued at over $180M (announced 2021) and Bristol Myers Squibb collaboration provide public partnership signals for pharmaceutical use cases
✓Peer-reviewed publications in journals such as Nature Medicine and The Lancet Digital Health provide scientific credibility relative to less-published AI biotech peers
✓Founded in 2016 with substantial reported funding and a global office presence, which may give institutional clients additional confidence in long-term vendor viability
✓Multimodal approach combining pathology, genomics, spatial-omics and clinical data is intended to capture biological complexity beyond single-modality platforms

👎 Common Concerns

⚠Exclusively enterprise-focused with no self-service tier, making it inaccessible to individual researchers, small biotech startups, or academic labs without partnership agreements
⚠Heavy dependency on hospital data partnerships means geographic coverage and data diversity are limited by the willingness and ability of institutions to participate in federated networks
⚠Drug discovery timelines remain 3-5+ years from target identification to clinical proof-of-concept despite AI acceleration, and no Owkin-originated drug has yet reached late-stage clinical trials
⚠No publicly available pricing or standard contract terms, making cost comparison with alternatives like Recursion or Insilico Medicine difficult for prospective clients
⚠Limited public disclosure of model performance metrics and validation data outside of published research papers, making independent assessment of platform accuracy challenging
⚠Regulatory approval for AI diagnostics varies by jurisdiction, and expanding beyond FDA-cleared products to additional cancer types and international markets involves lengthy timelines